Table 3.
Treatment-related adverse events in the two groups.
| Adverse events | Any grade | Grade 3 | ||||
|---|---|---|---|---|---|---|
| TACE-L-P group (n=41) | TACE-L group (n=40) | P | TACE-L-P group (n=41) | TACE-L group (n=40) | P | |
| Total | 38 (92.7) | 38 (95.0) | 1.000 | 15 (36.6) | 13 (32.5) | 0.699 |
| Related to TACE | 6 (14.6) | 7 (17.5) | 0.725 | 0 (0.0) | 0 (0.0) | – |
| New ascites | 3 (7.3) | 2 (5.0) | 1.000 | 0 (0.0) | 0 (0.0) | – |
| Pleural effusion | 2 (4.9) | 2 (5.0) | 1.000 | 0 (0.0) | 0 (0.0) | – |
| Inguinal hematoma | 2 (4.9) | 3 (7.5) | 0.977 | 0 (0.0) | 0 (0.0) | – |
| Biliary injury† | 1 (2.4) | 2 (5.0) | 0.983 | 0 (0.0) | 0 (0.0) | – |
| Related to drug* | 38 (92.7) | 37 (92.5) | 1.000 | 15 (36.6) | 13 (32.5) | 0.699 |
| Hypertension | 16 (39.0) | 14 (35.0) | 0.708 | 9 (22.0) | 8 (20.0) | 0.829 |
| Weight loss | 14 (34.1) | 11 (27.5) | 0.517 | 1 (2.4) | 0 (0.0) | 1.000 |
| Diarrhea | 13 (31.7) | 13 (32.5) | 0.939 | 0 (0.0) | 0 (0.0) | – |
| Hand-foot syndrome | 11 (26.8) | 13 (32.5) | 0.576 | 0 (0.0) | 0 (0.0) | – |
| Fatigue | 11 (26.8) | 9 (22.5) | 0.651 | 1 (2.4) | 0 (0.0) | 1.000 |
| Elevated AST | 11 (26.8) | 8 (20.0) | 0.468 | 0 (0.0) | 1 (2.5) | 0.494 |
| Decreased appetite | 10 (24.4) | 9 (22.5) | 0.841 | 1 (2.4) | 1 (2.5) | 1.000 |
| Hypothyroidism | 10 (24.4) | 8 (20.0) | 0.635 | 0 (0.0) | 0 (0.0) | – |
| Elevated ALP | 9 (22.0) | 11 (27.5) | 0.563 | 0 (0.0) | 0 (0.0) | – |
| Hypoalbuminemia | 9 (22.0) | 8 (20.0) | 0.829 | 0 (0.0) | 0 (0.0) | – |
| Abdominal pain | 9 (22.0) | 8 (20.0) | 0.829 | 0 (0.0) | 1 (2.5) | 0.494 |
| Pruritus | 9 (22.0) | 4 (10.0) | 0.143 | 0 (0.0) | 0 (0.0) | – |
| Elevated ALT | 8 (19.5) | 9 (22.5) | 0.741 | 1 (2.4) | 0 (0.0) | 1.000 |
| Thrombocytopenia | 8 (19.5) | 8 (20.0) | 0.956 | 1 (2.4) | 2 (5.0) | 0.983 |
| Neutropenia | 8 (19.5) | 6 (15.0) | 0.591 | 2 (4.9) | 2 (5.0) | 1.000 |
| Proteinuria | 8 (19.5) | 6 (15.0) | 0.591 | 0 (0.0) | 0 (0.0) | – |
| Rash | 8 (19.5) | 4 (10.0) | 0.228 | 0 (0.0) | 0 (0.0) | – |
| Anemia | 7 (17.1) | 5 (12.5) | 0.562 | 0 (0.0) | 1 (2.5) | 0.494 |
| Lymphopenia | 7 (17.1) | 4 (10.0) | 0.353 | 1 (2.4) | 0 (0.0) | 1.000 |
| Elevated TBi | 6 (14.6) | 7 (17.5) | 0.725 | 1 (2.4) | 1 (2.5) | 1.000 |
| Nausea | 6 (14.6) | 6 (15.0) | 0.963 | 0 (0.0) | 0 (0.0) | – |
| Elevated GGT | 6 (14.6) | 5 (12.5) | 0.779 | 0 (0.0) | 0 (0.0) | – |
| Ventosity | 6 (14.6) | 5 (12.5) | 0.779 | 1 (2.4) | 0 (0.0) | 1.000 |
| Arthralgia | 6 (14.6) | 5 (12.5) | 0.779 | 0 (0.0) | 0 (0.0) | – |
| Vomiting | 5 (12.2) | 6 (15.0) | 0.713 | 0 (0.0) | 0 (0.0) | – |
| Gingival bleeding | 5 (12.2) | 6 (15.0) | 0.713 | 0 (0.0) | 0 (0.0) | – |
| Dysphonia | 4 (9.8) | 6 (15.0) | 0.704 | 0 (0.0) | 0 (0.0) | – |
| Edema | 3 (7.3) | 4 (10.0) | 0.973 | 0 (0.0) | 0 (0.0) | – |
| Elevated uric acid | 3 (7.3) | 1 (2.5) | 0.626 | 0 (0.0) | 0 (0.0) | – |
| Insomnia | 2 (4.9) | 2 (5.0) | 1.000 | 0 (0.0) | 0 (0.0) | – |
| Infusion reaction | 2 (4.9) | – | – | 0 (0.0) | – | – |
| Hyperglycemia | 1 (2.4) | 0 (0.0) | 1.000 | 0 (0.0) | 0 (0.0) | – |
| Pneumonitis | 1 (2.4) | 0 (0.0) | 1.000 | 1 (2.4) | 0 (0.0) | 1.000 |
Data were presented as n (%). †Included intrahepatic biliary dilatation and biloma; *Referred to lenvatinib and/or PD-1 inhibitor. TACE-L-P, transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor; TACE-L, transarterial chemoembolization combined with lenvatinib; TACE, transarterial chemoembolization; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; TBi, total bilirubin; GGT, γ-glutamyl transpeptidase.